Randy Scott, Invitae Corporation: Interview Q&A
Q: Invitae wants to be the Amazon of genetic testing. What does that exactly mean and what does Invitae do that is different from other companies to achieve this? A: Invitae is proactively driving down the cost of genetic testing in order to make it more affordable...
read morePMWC 2017 Silicon Valley is a MUST-ATTEND Event – here is why!
With the great progress we see in the field of Precision Medicine, there are still critical issues that we need to overcome whether it is the definition of value-based pricing, the successful development and application of clinical biomarkers, working in patient...
read moreFrederic Pla, Genomic Health: Interview Q&A
Q: What attracted you to join Genomic Health and what is your role? A:Genomic Health shifted the paradigm in cancer management, helping over 700,000 patients optimize their treatment decisions, and pioneering a new business model that has been followed by many...
read moreClive Morris, Inivata Ltd.: Interview Q&A
Q: What attracted you to join Inivata and what is your role? Chief Medical Officer, CMO A: I was attracted to Inivata to help progress a technology I see can make a major impact in improving how we diagnose and manage patients with cancer. The field of liquid biopsy,...
read moreLincoln Nadauld, Intermountain Healthcare: Interview Q&A
Q: What were the motivations to create the Oncology Precision Network (OPeN)? A: As we began implementing precision oncology at our hospitals and clinics throughout Intermountain Healthcare, we quickly began to realize that there are certain variants or mutations in a...
read moreQ&A article: James Allison, MD Anderson Cancer Center
Does Immunotherapy Measure Up to the Hype? Brigitte Ganter, PhD Disclosures | October 27, 2016 Editor’s Note: The emergence of immunotherapy has redefined cancer medicine. Among those who continue to redefine this expanding arena of clinical research, James P....
read moreDr. James Allison, MD Anderson: We Are Still Missing A Good Baseline
Dr. James Allison of MD Anderson Cancer Center, considered by many to be the “father of immunotherapy” is a recipient of the PMWC 2017 Pioneer Award. In his interview published earlier this week on Medscape highlighted some of the key focus areas of PMWC 2017 Silicon...
read moreAre Payors Finally Heeding the Call to Offer More Responsive Policies?
Major Announcement – Medicare Makes Genetic Testing More Affordable and Accessible “Reimbursement policies threaten the development of molecular diagnostics as a critical element in making precision medicine a reality. The payors are beginning to feel the...
read moreIs Immunotherapy the 4th Pillar of Oncology?
In contrast to the three traditional pillars of cancer treatment (surgery, radiotherapy, and chemotherapy), cancer immunotherapy is a relatively young field, yet it is considered a huge game-changer – as it is in the process of changing how we treat cancer....
read moreNote from Dr. Keith Yamamoto, PMWC 2017 SV Program Chair
Times couldn’t be more exciting with the ongoing conceptualization and implementation of Precision Medicine, the revolutionary approach to research, health, and healthcare that is continuously evolving, driven in part by the Precision Medicine Initiative launched and...
read more
